Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing new deals

Rough­ly five weeks af­ter buy­ing out Askle­pios — al­so known as AskBio — for up to $4 bil­lion, Bay­er is ham­mer­ing home its fo­cus on cell and gene ther­a­pies.

The Big Phar­ma an­nounced Wednes­day that it is es­tab­lish­ing a cell and gene ther­a­py plat­form with­in its phar­ma­ceu­ti­cals di­vi­sion in or­der to con­sol­i­date all of its re­lat­ed projects un­der one um­brel­la. Re­searchers will con­tin­ue work­ing and de­vel­op­ing ex­per­i­men­tal drugs on their own, Bay­er said, while the ex­ecs will lay out and de­fine the over­all strat­e­gy and look to swing some more deals.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN